Equities Research - Market Bulletin
September 4, 2020 3:38 PM ET
Valeo Pharma Inc. Approved for Sale of HesperCo™, Immune System
Support Scientifically Demonstrated
This Market Bulletin is an
update to our September 2, 2020 advisory; excerpt copy:
Shares of Valeo Pharma Inc. (CSE: VPH) (Frankfurt: VP2) are
poised for upside revaluation to reflect the major
‘company–maker’ potential in HesperCo™ as the market figures out
it is set to be the subject of Covid-19 clinical trial.
Valeo will benefit immensely by the direct association of the
licensed product name being the same as that of the trial. Note:
Conceivably, in the near-term en masse, we may see a scenario
develop whereby frontline workers and people concerned about the
virus will want to take HesperCo™ proactively and certainly if
infected to alter the viral kinetics; inhibit replication, and
modulate the inflammatory response by down regulating the
cytokine storm. Hesperidin (the compound making up HesperCo™) is
set to undergo Covid19 clinical trials to further evidence its
support of the immune system leading to speculation HesperCo™
will become a go-to tool in dealing with early-stage infection;
scientific academic research supports that in the lag-time
before antibodies kick-in hesperidin meaningfully keeps at bay
the number of viruses the body has to neutralize.
Valeo Pharma Inc. (CSE: VPH)
(Frankfurt: VP2) is a fully integrated specialty Canadian
pharmaceutical company. On Thursday September 3, 2020
Valeo Pharma announced that it has received a Natural Product
Licence approval from Health Canada authorizing the sale of its
bioflavonoid formulation, HespercoTM, in Canada
(<==click hyperlink to see related news).
HespercoTM capsules contain a powerful antioxidant that
can be taken for immune system support.
HespercoTM capsules are expected to be commercially available by end
of September 2020, and pre-sales now available at the
https://hesperco.com store online.
Figure 1. (above) Image of Valeo's HesperCo(TM)
product sourced from
Q. What is HESPERCO™?
A. HESPERCO™ is an approved natural product that contains
500mg of hesperidin, a potent antioxidant bioflavonoid with proven
immune support properties. Hesperidin is a powerful antioxidant
derived from immature citrus fruit.
Benefits of Hesperidin:
The health benefits of hesperidin were recognized early after it’s
discovery; it was initially erroneously identified as a vitamin,
“vitamin P”. Over the past decade, numerous scientific studies have
validated the health benefits of hesperidin. Research has
demonstrated that hesperidin may be effective in supporting immune
Hesperidin is not being advanced by any big pharma as it is a public
domain compound, and thus can’t be turned around and sold for $100 a
pill. Valeo Pharma is not saying much about HesperCo™ at this point
in time apart from it ‘supporting the immune system’, which is a
catch-all phrase that basically encompasses a number of
possibilities without making claims, but one look at the HesperCo™
manufacturer Ingenew’s corporate website
and it is clear Hesperidin has copious amounts of academic research
from multiple sources supporting the role it plays in various phases
of Covid19 viral infection.
See Valeo’s partner PDF on SARS-COV-2 (a.k.a. Covid-19) and how it
infects the host:
<==click to view
See Valeo’s partner PDF on hesperidin and scientific literature
search looking back at SARS-COV (previous strains):
<==click to view
The name ‘HesperCo’ (TM) comes from the upcoming clinical trial
testing hesperidin on Covid19 (coronavirus) patients that Ingenew
will apparently be involved with (details still to be announced, but
they make reference to it at
Below is a synopsis of key academic research that is already
understood about hesperidin;
We urge the reader to view the above PDF’s from Valeo’s partner and
the supporting index of 123 research papers. The following is
what we believe to be the understanding of the objectives of the
HesperCo™ trial; in summary (not making health claims here, just
stating the objectives of a trial based on known scientific
research), hesperidin can prominently assist in the viral and
patient inflammatory response phases, and potentially hesperidin
covers all 4 phases of the covid19 progression.
All phases of viral infection appear to be affected in some way
by hesperidin and that the earlier the patient is on hesperidin the
better. When you are asymptomatic and start having fever and
cough, you are in the viral response phase. Fever and cough marks
the inflammatory response phase. The presence of hesperidin
interferes with what would otherwise be an exponential cascade of
viral S-Spike binding and HR1-HR2 replication. Since the body has no
vaccine present (no memory/blueprint about how to respond) the
initial lag time is when the presence of hesperidin can drastically
reduce the viral load and can prevent matters from getting critical.
1) Hesperidin prevents the penetration (binding) of the novel
coronavirus S-Spike protein into the cell’s Ace2 protein receptor:
The spike region binding domain of the virus is the part that
connects to the Ace2 receptor of a cell. Hesperidin has scientific
support that indicates it causes interference in the shallow pockets
that the spike attempts to bind with.
2) Hesperidin inhibits the replication of the virus:
Hesperidin has scientific support in literature that it neutralizes
or inhibits the 3CL protease, also referred to as the Mpro. There
are now at least 5 groups that have shown, plus in vitro evidence,
that hesperidin can essentially inhibit the 3CL probe replication
protein. Once infected, the 3CL is a key protein in the virus
replication, and with hesperidin present to cause a neutralizing
effect on the 3CL, replication is dramatically hindered.
3) Hesperidin modulates inflammation and biomarkers: The
coronavirus affects multiple organs; infecting and dysregulating the
CNS System, the respiratory system, cardiovascular system, etc.
Hesperidin has scientific evidence that it can play an active role
in modulating inflammation and biomarkers, which by default reduces
the cytokine storm.
4) Hesperidin attenuates ventilator induced acute lung injury:
Although hesperidin is ideally taken orally for EARLY–stage
mitigation, it has significant scientific support in its ability to
attenuate ventilator induced acute lung injury. If a person is at
such an acute stage they would not be taking HesperCo™ as currently
the product is over-the-counter oral, but it is comforting to know
the science is there on that front too. There is already talk of an
alternate form of delivery for the product under development.
------ ------ ------
------ ------ ------ ------ ------
What does all this mean for investors in Valeo Pharma Inc.?
HesperCo™ is trademarked by Ingenew and licensed to Valeo. Valeo has
world-wide rights, it has received its licensing now from Health
Canada, it already has product and packaging ready for delivery, is
expected to launch within weeks, and is expected to follow into the
USA shortly thereafter. Ingenew’s clinical trial is “the HesperCo™
Clinical Trial”. From what is known to date academically Ingenew and
Valeo appear to have the potential for a home-run, this has the
earmarks of a run-away freight train home-run company-maker. Keep
your eye on shares of CSE:VPH.
Valeo Pharma Inc. shares (CSE:VPH) have already ripped higher
recently based on the positive outlook of projected sales from its
in-licensing product pipeline. The HesperCo™ addition will only
drive the share price higher. The management team are experienced,
successful, and sophisticated industry veterans that know how to vet
winning in-licensing relationships and minimize risk (in-licensing
eliminates all development risk). The HesperCo™ product is a slight
departure from Valeo’s traditional drug business (marketed to
hospitals and doctors) in that HesperCo™ has been issued a NHP from
Health Canada and will be available over-the-counter everywhere and
thru online sales. Valeo has a good commercial team able to handle
all aspects of the coming HesperCo™ sales ramp-up; its head of
commercial operations ran the retail over-the-counter division for
Schering-Plough several years ago, before joining Valeo.
------ ------ ------
------ ------ ------ ------ ------
Valeo Pharma is executing well and on a meteoric-like rise:
Valeo’s m.o. is to vet proven pharma opportunities globally and
makes inlicensing deals. With several of the Company’s new drug
products having advanced to the monetization/launch phase recently, Valeo is on-track to reach cash flow profitability by the end of its
fiscal year (which is this October-2020).
Valeo Pharma is fast moving, nimble and dynamic; it maintains,
in-house, all the necessary capabilities and infrastructure to
register and manage a drug through all stages of commercialization.
The Company has several products in the market now, has a pipeline
of products coming to market over the next several months, plus the
business development team is active with yet unannounced deals that
are currently being negotiated now.
VPH is in the process of closing on a C$6M capital raise, a bought
deal agreement with a syndicate of underwriters, characterized with
strong institutional involvement. The proceeds will be used for both
working capital and growth as needed. Funding will be primarily used
for growth capital needs; e.g. inventory growth, product acquisition
growth, and licensing growth purposes.
Valeo is in the process of maturing into a more mainstream
pharmaceutical growth investment vehicle. The company is stronger
financially now, has repeatedly demonstrated the ability to execute
on a plan, has proven access to capital, and in turn is increasingly
more attractive to licensing partners and prospects -- the scenario
is self-reinforcing and is apt to lead to additional continued,
steady, new, and quality product pipeline business development. A
number of institutional funds have recently indicated an interest in
getting involved with Valeo. Additionally, Valeo will soon be
expanding to trade in the US on the OTCQB exchange.
For further insight on Valeo Pharma Inc. the following URLs have
Recent Technology Journal article:
This bulletin may contain
forward-looking statements regarding future events that involve risk and
uncertainties. Readers are cautioned that these forward-looking statements are
only predictions and may differ materially from actual events or results.
Articles, excerpts, commentary and reviews herein are for information purposes
and are not solicitations to buy or sell any of the securities mentioned.